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Commonly used medications and endometrial
cancer survival: a population-based cohort
study
Omolara B Sanni*,1, U´na C Mc Menamin1, Chris R Cardwell1, Linda Sharp2, Liam J Murray1
and Helen G Coleman1
1Cancer Epidemiology and Health Services Research Group, Centre for Public Health, Royal Victoria Hospital, Queen’s University
Belfast, Block B, Grosvenor Road, Belfast, Northern Ireland and 2Institute of Health and Society, Newcastle University, Baddiley-
Clark Building, Richardson Road, Newcastle upon Tyne NE2 4AX, UK
Background: Increasing incidence and new indications for existing drugs make it important to identify new adjuvant therapies for
endometrial cancer (EC).
Methods: This is a prospective cohort study of 3058 newly diagnosed EC cases from 1998 to 2010, identified through record
linkages between the UK Clinical Practice Research Datalink, the National Cancer Research Datalink and death registrations from
the Office of National Statistics. Using Cox regression models, unadjusted and adjusted hazard ratios (HRs) and 95% confidence
intervals (CIs) were calculated for EC-specific survival.
Results: Over a mean 6.1 (range 1–16) years of follow-up, there were 394 EC-specific deaths. There was no evidence of a
significant association between post-diagnostic use of statins (adjusted HR 0.83, 95% CI 0.64, 1.08), b-blockers (adjusted HR 0.86,
95% CI 0.65, 1.13) or low-dose aspirin (adjusted HR 0.91, 95% CI 0.69, 1.20) and EC survival before or after adjustment for
confounders. There were also no evidence of a dose–response association between these drug groups and EC survival.
Conclusions: In this large UK population-based study, no significant associations were observed for post-diagnostic use of statins,
b-blockers or low-dose aspirin and EC survival.
Endometrial cancer (EC) is the fifth most common malignancy
among women worldwide (Ferlay et al, 2015). There were
B320 000 new cases diagnosed in 2012 and its incidence is
projected to increase to around half a million by the year 2035
(Ferlay et al, 2015). The risk of developing EC is significantly
increased in women with prolonged or excessive exposure to
oestrogen (Dossus et al, 2010). Most cases of ECs are diagnosed at
an early stage (Morice et al, 2016) and 5-year overall survival is
relatively high, ranging from 74 to 91% in stages I or II but this falls
to 20–26% in stage IV disease (Siegel et al, 2015). The majority of
EC cases undergo hysterectomy (Morice et al, 2016) and although
5-year survival rates are relatively good, there is room for
improvement and in particular, identification of additional
adjuvant treatments.
In recent years, new indications have been found for existing
drugs in the process commonly referred to as drug repositioning,
redirecting, reprofiling or repurposing (Gupta et al, 2013).
Research has shown that some commonly prescribed medications
that were originally indicated for other conditions may offer
beneficial effects in terms of risk reduction and improved survival
for different types of cancers (Gao et al, 2004, Cardwell et al, 2013,
Lavie et al, 2013).
Three such classifications of drugs that have shown particular
promise for potential adjuvant therapies for cancer are statins,
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aspirin and b-blockers. Statins are inhibitors of 3-hydroxy-3-
methylglutaryl coenzyme A reductase and are primarily used as a
cholesterol-lowering medication (Rutishauser, 2011). Statins have
also been shown to have anti-proliferative and pro-apoptotic
effects (Thibault et al, 1996). Recently, simvastatin was demon-
strated to have significant anti-proliferative and anti-metastatic
effects in EC cells (Schointuch et al, 2014). This suggests that
statins may be useful in improving prognosis for EC patients.
Earlier epidemiological studies have reported conflicting results for
statin use in relation to survival among EC patients. One small
Israeli study of 274 incident gynaecological cancers reported a 65%
reduced risk of all-cause mortality (Lavie et al, 2013). This study
included only a small sample of cases from a single institution and
medication use was not treated as a time-dependent variable,
which created a potential for immortal time bias. Another
retrospective cohort study, which included 985 EC cases conducted
in the United States, reported better disease-specific survival
(Nevadunsky et al, 2015) among users of statins compared with
non-users. This study also featured patients from a single
institution and medication use was assessed at time of diagnosis
only. In contrast, another retrospective cohort study of 2987
endometrial cases who received a hysterectomy within 6 months of
diagnosis and survived at least 90 days after surgery, found no
significant association between statin use and overall survival
(Yoon et al, 2015).
b-Blockers, which are commonly prescribed for management of
heart disease and hypertension (Aronow, 2010), have been
suggested to have a role in the reduction of tumour occurrence,
metastasis and cancer-specific mortality among breast cancer
patients (Barron et al, 2011, Melhem-Bertrandt et al, 2011).
However, as far as we are aware, no study has examined whether
the use of b-blockers is associated with survival in EC.
The influence of inflammation (Modugno et al, 2005) and
platelet interaction with tumour cells (Gay and Felding-
Habermann, 2011) on the development of cancer has resulted in
the suggestion that use of aspirin, a commonly prescribed anti-
platelet medication, may be protective against EC development
(Neill et al, 2013). In a recent multicentre retrospective study,
which included 1687 women who underwent surgical staging for
EC, low-dose aspirin users were reported to have improved
disease-specific survival compared with non-users (hazard ratio
(HR) 0.23, 95% confidence interval (CI) 0.08, 0.64) (Matsuo et al,
2016). In this study, medication use was not assessed over a long
period of time and number of prescriptions was also not assessed.
In addition, the study had a relatively short follow-up time.
Overall, there is a paucity of evidence from observational studies
assessing the association between use of statins, b-blockers or low-
dose aspirin and EC survival; there is a need for large population-
based studies to investigate whether EC patients would benefit
from a protective effect of these drugs.
The aim of this population-based study was to assess the
associations between post-diagnostic use of statins, b-blockers or
aspirin and cancer-specific survival among newly diagnosed cases
of EC
MATERIALS AND METHODS
Data sources. A large prospective cohort study utilising linkages
between the UK Clinical Practice Research Datalink (CPRD,
previously known as GPRD), the National Cancer Research
Datalink (NCDR) and the Office of National Statistics (ONS)
death registrations was conducted. The NCDR data contains
information on all incident primary cancers in England, including
date and site of cancer, tumour grade and stage, and cancer-
directed treatment received. The CPRD is the world’s largest
computerised data set of anonymised longitudinal primary care
records. It includes routinely collected high-quality data on patient
demographics, clinical diagnoses and prescriptions in England
(Jick et al, 1991, Boggon et al, 2013). Information on deaths was
obtained from linkages to ONS mortality data including date and
cause of death. Ethical approval for all observational studies
conducted using CPRD data has been obtained from a multicentre
research ethics committee.
Study design. Cases with an incident diagnosis of EC confirmed
between January 1998 and December 2010 through cancer registry
linkage were identified using ICD codes C54, C55 or 182. Cases
with a previous NCDR-registered cancer diagnosis (excluding
in situ neoplasms and non-melanoma skin cancers) were excluded.
Cases were also excluded if their date of diagnosis preceded CPRD
research quality records or if death registration records were
unavailable. Cases who died within the first year after cancer
diagnosis were also excluded (sensitivity analysis was conducted
varying this interval), as it seemed unlikely that short term post-
diagnostic medication usage could influence such deaths.
Cases were followed up from 1 year after EC diagnosis until
death, end of registration with the general practice, last date of data
collection from general practice (as patients would not have drug
exposure data after this) or end of ONS follow-up (April 2014).
Exposure data. GP prescription data within the CPRD was used
to determine post-diagnostic statins, b-blockers and low-dose
aspirin use according to the British National Formulary (British
Medical Association and the Royal Pharmaceutical Society of Great
Britain: British National Formulary). Medications were treated as
time-varying covariates, in order to avoid immortal time bias
(Levesque et al, 2010). This bias relates to a length of time during
which the outcome of interest may not occur, i.e., if the time from
cohort entry to first exposure to a drug is improperly classified as
‘exposed’ when this time is actually ‘immortal’. A lag of 6 months
was applied to medication use, as recommended (Chubak et al,
2013), in order to exclude prescriptions received by patients in the
6 months before death (which may be due to changes due to end-
of-life treatment). Therefore, drug users were classified as non-
users until 6 months after first prescription and users thereafter.
The number of prescriptions was used as proxy to represent 1 year
of medication use (1–11 prescriptions) or more than 1 year use
(X12 prescriptions). Similarly, an individual was considered a
non-user before 6 months after first medication usage, a short-term
user from 6 months after first prescription to 6 months after the
12th prescription and a longer-term user after this time, excludes
deaths in the first year after cancer diagnosis.
Covariates. Clinical information on EC stage and grade were
taken from NCDR, in addition to data on cancer treatments
(surgery, chemotherapy and radiotherapy) received within the 6
months after cancer diagnosis. Smoking, alcohol and body mass
index (BMI) were derived from the most recent GP record within
the 10 years before EC diagnosis. Comorbidities before EC
diagnosis were extracted from GP-recorded clinical diagnoses
and were based on the comorbidity codes included in a recent
adaptation of the Charlson Comorbidity index for GPRD (Khan
et al, 2010). A measure of socioeconomic status was obtained from
deprivation measures within CPRD records which are based on
residential postcodes (using the 2004 index of multiple deprivation
for England) (Noble et al, 2004).
Data analysis. Cox regression models were used to derive HRs
and 95% CIs to assess post-diagnostic drug use and EC-specific
mortality. Analyses were conducted based on number of prescrip-
tions to assess potential dose–response relationships. Potential
confounders were considered in adjusted models, including age
and year of cancer diagnosis, treatment received within 6 months
of cancer diagnosis (surgery, chemotherapy or radiotherapy),
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deprivation (in quintiles), comorbidities and medication use after
diagnosis (statins, b-blockers and aspirin use, treated as time-
varying covariates). All analyses were repeated for all-cause
mortality.
As BMI is a well-known aetiological risk factor for EC, sub-
group analyses were conducted stratifying by BMI status (BMI
before diagnosis p25 and 425 kgm 2, respectively). Sensitivity
analyses were conducted including additional adjustment for
cancer stage (among individuals with available stage data) as a
proportion (B50%) of our cohort had missing data for stage due
to a lack of recording of cancer stage in some cancer registries.
Drug exposure lag time was also increased to 1 year in sensitivity
analysis. Further sensitivity analysis excluded patients with less
than 6 months follow-up after diagnosis (as opposed to 1 year).
Additional sensitivity analysis was conducted based upon drug
prescriptions in the year before diagnosis, not excluding deaths in
the first year after diagnosis with EC patients followed from
diagnosis to death, end of registration with the general practice, last
date of data collection from general practice or end of ONS follow-
up. Cox regression models were used to calculate HRs and 95% CIs
for medication use based upon prescriptions in the year before
diagnosis (restricted to individuals with at least 1 year of records
before diagnosis). An adjusted analysis for pre-diagnostic statin use
was also conducted, omitting stage, grade, cancer treatment from
adjustments for potential confounders to avoid over-adjustment
(Weinberg, 1993, Schisterman et al, 2009), as these could be on the
causal pathway for EC-specific mortality.
RESULTS
Patient cohort. There were a total of 3646 EC cases identified
between 1998 and 2010. A total of 588 of these were excluded due
to having less than 1 year of follow-up after cancer diagnosis. This
left 3058 cases, in whom 394 EC-specific deaths and 809 deaths
from any cause occurred during a mean follow-up of 6.1 years
(ranging from 1 to 16.3 years) (Supplementary Figure 1).
Characteristics of all patients by statins, b-blockers and low-dose
aspirin use are presented in Table 1.
Users of statins, b-blockers and/or low-dose aspirin were more
likely to be older, overweight/obese and have a history of diabetes
than non-users (Table 1). Statin and b-blocker (but not low-dose
aspirin) users were slightly more likely to have consumed alcohol,
compared with non-users (57–58% vs 55%, respectively). Of the
three medication groups, only statin users were more likely to be
diagnosed with early stage disease (stage 1 37% vs 32%) and with
well differentiated tumours (34% vs 29%) compared with non-
users. Statin and low-dose aspirin (but not b-blocker) users were
more likely to be from deprived socio-economic backgrounds than
non-users (14% vs 10%). There appeared to be no marked
difference between users of the three medication groups by
smoking status before cancer diagnosis and type of cancer
treatment received within 6 months of cancer diagnosis.
Statin users were more likely to use b-blockers and low-dose
aspirin. Although users of b-blockers were more likely to use low-
dose aspirin, they were less likely to use statin. A Kaplan–Meier
survival curve was used to assess EC-specific survival by disease
stage at diagnosis (Supplementary Figure 2). As expected, cancer
stage at diagnosis was strongly associated with cancer-specific
mortality.
Association between statin use after diagnosis and EC survival.
Associations between statin use and EC survival are presented in
Table 2. In the unadjusted model, there was little evidence of an
association between post diagnostic statin use and EC-specific
survival (HR 1.05, 95% CI 0.83, 1.31). When relevant confounders
were included in the model, no significant reduction in EC
mortality was observed (adjusted HR 0.83, 95% CI 0.64, 1.08).
There appeared to be no evidence of a dose relationship between
increasing number of statin prescriptions and EC-specific survival
(Table 2). Similarly, null associations were observed between
medication use and risk of all-cause death. Similar results were
observed for pre-diagnostic use of statins and EC-specific or overall
survival (Supplementary Table 1)
Association between b-blockers use after diagnosis and EC
survival. Associations between b-blocker use and EC-specific
survival are presented in Table 2. In the unadjusted or adjusted
models, there appeared to be limited evidence of an association
between post-diagnostic use of b-blockers and EC-specific survival
(unadjusted: HR 0.97, 95% CI 0.77, 1.22; adjusted: HR 0.87, 95% CI
0.68, 1.10). There was also no evidence of a dose-response
relationship between use of b-blockers and EC-specific survival
(Table 2). There was no association between b-blockers use and all-
cause mortality (adjusted HR 1.04, 95%CI 0.89, 1.22). There also
appeared to be no significant association when pre-diagnostic use
of b-blockers was assessed in relation to EC-specific or overall
survival (Supplementary Table 1).
Association between low-dose aspirin use after diagnosis and EC
survival. Associations between low-dose aspirin use and EC-
specific survival are presented in Table 2. In the unadjusted model,
there appeared to be no significant association between post-
diagnostic use of low-dose aspirin and EC-specific survival
(unadjusted HR 1.14, 95% CI 0.90, 1.44). After adjusting for
confounders, the association between low-dose aspirin and EC
survival remained nonsignificant (adjusted HR 0.91; 95% CI 0.69,
1.20). There was also no evidence of a dose–response relationship
between the use of low-dose aspirin and EC-specific survival
(Table 2). There was no evidence of an association between the use
of low-dose aspirin and death from any cause (Table 2). When we
assessed pre-diagnostic use of low-dose aspirin, we found no
significant associations for EC-specific or overall survival
(Supplementary Table 1).
Sensitivity and sub-group analyses. Results from sensitivity/sub-
group analyses are presented in Table 3. In sub-group analysis, the
previously observed null associations between use of statins, b-
blockers or low-dose aspirin and EC-survival remained in stratified
analysis by BMI category.
There was also no evidence of association between use of these
drugs and EC survival after additionally adjusting for cancer stage
(among individuals with available stage data) in sensitivity analyses
or when the lag was increased to 1 year (Table 3).
DISCUSSION
The results from this UK population-based cohort study show no
significant associations between post-diagnostic use of statins,
b-blockers, and low-dose aspirin and EC survival. In addition,
there was no evidence of a dose–response relationship with
increasing number of prescriptions for EC survival and any of the
drug groups studied.
Statins are thought to inhibit the melavonate pathway, thereby
mitigating cancer cell growth and prevent the prenylation of the
essential proteins involved in the migration and proliferation of
cancer cell (Corcos, Le Jossic-corcos, 2013). Despite this proposed
mechanism, the current study detected no significant association
between statin use and EC survival. This is in line with, and builds
upon, findings from a previous US cohort study that reported a
slight nonsignificant reduced risk of death from any cause among
statin users compared with non-users (Yoon et al, 2015).
However, other epidemiological studies have suggested a
protective association between use of statin and overall or
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Table 1. Characteristics of endometrial cancer patients by statin, b-blocker and low-dose aspirin use after cancer diagnosis
Statin use after diagnosis b-Blocker use after diagnosis
Low-dose aspirin use after
diagnosis
Total Ever n (%) Never n (%) Ever n (%) Never n (%) Ever n (%) Never n (%)
Characteristics (n¼3058) (n¼1134) (n¼1924) (n¼928) (n¼2130) (n¼859) (n¼2199)
Year of diagnosis
1998–2000 400 (13) 132 (12) 268 (14) 139 (15) 261 (12) 132 (15) 268 (12)
2001–2003 671 (22) 255 (23) 416 (22) 232 (25) 439 (21) 234 (27) 437 (20)
2004–2006 782 (26) 302 (27) 480 (25) 241 (26) 541 (25) 231 (27) 551 (25)
2007–2009 895 (29) 344 (30) 551 (29) 253 (27) 642 (30) 222(26) 673 (31)
2010 310 (10) 101 (9) 209 (11) 63 (7) 247 (12) 40 (5) 270 (12)
Age at diagnosis (years)
o50 224 (7) 37 (3) 187 (10) 36 (4) 188 (9) 15 (2) 209 (10)
50–59 747 (24) 217 (19) 530(28) 188 (20) 559 (26) 126 (15) 621 (28)
60–69 1009 (33) 411 (36) 598 (31) 289 (31) 720 (34) 246 (29) 763 (35)
70–79 738 (24) 359 (32) 379 (20) 276 (30) 462 (22) 310 (36) 428 (20)
80–89 315 (10) 109 (10) 206 (11) 132 (14) 183 (9) 154 (18) 161 (7)
X90 25 (1) 1 (0.1) 24 (1.3) 7 (1) 18 (1) 8 (1) 17 (1)
Figo stage
1 1039 (34) 421 (37) 618 (32) 306 (33) 733 (34) 284 (33) 755 (34)
2 283 (9) 111 (10) 172 (9) 104 (11) 179 (8) 78 (9) 205 (9)
3 189 (6) 50 (4) 139 (7) 44 (5) 145 (7) 40 (5) 149 (7)
4 19 (1) 4 (0.4) 15 (1) 6 (1) 13 (1) 4 (1) 15 (1)
Grade
I (well differentiated) 938 (31) 380 (34) 558 (29) 282 (30) 656 (30) 269 (31) 669 (30)
II (moderately differentiated) 989 (32) 377 (32) 612 (33) 315 (34) 674 (32) 269 (31) 720 (33)
III (poorly differentiated) 515 (17) 161 (14) 354 (18) 128 (14) 387 (18) 138 (16) 377 (17)
IV (undifferentiated) 16 (1) 6 (1) 10 (1) 4 (0.4) 12 (1) 6 (1) 10 (1)
Missing 600 (20) 210 (19) 390 (20) 199 (21) 401 (19) 177 (21) 423 (19)
Treatment within 6 months of cancer diagnosis
Surgery 2778 (91) 1033 (91) 1745 (90) 840 (91) 1938 (91) 776 (90) 2002 (91)
Chemotherapy 216 (7) 56 (5) 160 (8) 47 (5) 169 (8) 37 (4) 179 (8)
Radiotherapy 856 (28) 301 (27) 555 (29) 258 (28) 598 (28) 227 (26) 629 (29)
Table 2. Association between post-diagnostic statin, b-blockers and low-dose aspirin usage, and cancer-specific and all-cause
mortality in endometrial patients
Cancer-specific mortality All-cause mortality
Medication usage after diagnosis
Cancer-
specific
deaths
All
patients
Unadjusted HR
(95% CI) P
Adjusted
a
HR
(95% CI) P
All-
cause
deaths
Unadjusted HR
(95% CI) P
Adjusted
a
HR (95% CI) P
Statins
Statin non-user 288 1924 1.00 1.00 542 1.00 1.00
Statin userb 106 1134 1.05 (0.83, 1.31) 0.67 0.83 (0.64, 1.08) 0.07 267 1.26 (1.08, 1.46) 0.003 0.91 (0.77, 1.09) 0.32
Statin non-user 288 1924 1.00 1.00 542 1.00 1.00
Statin use 1–11 prescriptionsc 53 291 1.09 (0.81, 1.46) 0.58 0.88 (0.64, 1.22) 0.44 111 1.26 (1.03, 1.55) 0.03 0.97 (0.77, 1.21) 0.79
Statin use X12 prescriptionsc 53 843 1.01 (0.75, 1.37) 0.94 0.78 (0.55, 1.10) 0.16 156 1.25 (1.04, 1.50) 0.02 0.87 (0.70, 1.08) 0.20
b-blockers
b-blocker non-user 295 2130 1.00 1.00 543 1.00 1.00
b-blocker userb 99 928 0.97 (0.77, 1.22) 0.77 0.87 (0.68, 1.10) 0.24 266 1.31 (1.13, 1.53) o0.0001 1.04 (0.89, 1.22) 0.60
b-blocker non-user 295 2130 1.00 1.00 543 1.00 1.00
b-blocker use 1–11 prescriptionsc 50 279 1.01 (0.74, 1.36) 0.97 0.93 (0.68, 1.27) 0.65 102 1.19 (0.96, 1.47) 0.12 1.01 (0.81, 1.26) 0.91
b-blocker use X12 prescriptionsc 49 649 0.93 (0.68, 1.27) 0.65 0.80 (0.58, 1.11) 0.18 164 1.42 (1.19, 1.70) o0.0001 1.06 (0.88, 1.29) 0.52
Low-dose aspirin
Low-dose aspirin non-user 304 2199 1.00 1.00 547 1.00 1.00
Low-dose aspirin userb 90 859 1.14 (0.90, 1.44) 0.28 0.91 (0.69, 1.20) 0.52 262 1.66 (1.43, 1.93) o0.001 1.10 (0.92, 1.31) 0.28
Low-dose aspirin non-user 304 2199 1.00 1.00 547 1.00 1.00
Low-dose aspirin use 1–11 prescriptionsc 54 325 1.17 (0.87, 1.56) 0.30 0.95 (0.69, 1.31) 0.76 120 1.45 (1.19, 1.77) o0.001 1.00 (0.81, 1.25) 0.94
Low-dose aspirin use X12 prescriptionsc 36 534 1.10 (0.77, 1.57) 0.60 0.85 (0.58, 1.26) 0.72 142 1.92 (1.58, 2.32) o0.001 1.21 (0.98, 1.50) 0.08
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio.
aAdjusted for year of diagnosis, age at diagnosis, surgery within 6 months, radiotherapy within 6 months, chemotherapy within 6 months, deprivation (in fifths), comorbidities (before diagnosis,
including cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, myocardial infarction, peptic ulcer disease, peripheral vascular disease and renal disease),
medication use after diagnosis (time varying, including statins, b-blockers and low-dose aspirin).
bMedication use modelled as a time-varying covariate. An individual was considered a non-user before 6 months after first medication usage and a user after this time, excludes deaths in the 1
year after cancer diagnosis.
cMedication use modelled as a time varying covariate. An individual was considered a nonuser before 6 months after first medication usage, a short-term user from 6 months after first
prescription to 6 months after the 12th prescription and a longer-term user after this time, excludes deaths in the first year after cancer diagnosis.
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disease-free survival in EC cases (Lavie et al, 2013, Nevadunsky
et al, 2015). In the CITOUS study conducted in Israel, Lavie et al
(2013) reported an association between statin use and reduced risk
of death from any cause (HR 0.35, 95% CI 0.12, 0.96). However,
that study included a relatively small sample of cases from a single
institution and there was also potential for immortal time bias as
drug use was not treated as a time-dependent variable. This bias
relates to a length of time during which the outcome of interest
may not occur, i.e., if the time from cohort entry to first exposure
to a drug is improperly classified as ‘exposed’ when this time is
actually ‘immortal’ (in that an individual has to be alive in order to
be classed as exposed). Our analysis avoided this particular bias by
treating all drug exposures as time-varying covariates. In another
US retrospective cohort study including 985 EC cases, Nevadunsky
et al (2015) reported improved disease-free survival among statin
users compared with non-users. However, this was also a single
institution study and, importantly, only one exposure time point
(statin use at diagnosis only) was used to determine drug use
(Nevadunsky et al, 2015), whereas in the current study, medication
use was assessed over an extended time period and by number of
prescriptions.
This is the first study to assess the relationship between the use
of b-blockers and EC-specific mortality. Previous studies have
suggested that pre- (Powe et al, 2010, Barron et al, 2011) and
post-diagnostic (Melhem-Bertrandt et al, 2011, Cardwell et al,
2013) b-blockers use may have a part in reduction of tumour
occurrence, metastasis and cancer-specific mortality among breast
cancer patients (Powe et al, 2010, Barron et al, 2011, Cardwell et al,
2013). A recent retrospective multi-centric study concluded that
the use of any type of b-blocker resulted in improved disease-
specific survival during the first year following diagnosis among
women with epithelial ovarian cancer (Watkins et al, 2015). This is
consistent with preclinical studies that have shown the activation of
adrenergic receptors results in the growth and progression
of ovarian cancer (Watkins et al, 2015). However, extrapolation
of these mechanisms to EC may not be applicable, as there was no
evidence of an association between use of b-blockers and EC
survival in this study.
In a recent multicentre study, Matsuo et al (2016) reported a
significant association between the use of low-dose aspirin and EC
survival. In the study, users of low-dose aspirin were reported to
have improved disease-specific survival compared with non-users
(HR 0.23 95% CI 0.08, 0.64) (Matsuo et al, 2016). However,
medication use was not assessed over an extended time period, it
was determined only at diagnosis. Furthermore, the authors were
unable to assess frequency of drug use and follow-up period for the
study was relatively short (median 31.5 months), whereas in the
current study with a mean follow-up period of 6.1 years and
Table 3. Sensitivity analyses for association between statins, b-blockers and low-dose aspirin use and cancer-specific mortality in
endometrial cancer patients
Analysis
Cancer-specific
deaths All patients Person years
Adjusteda HR
(95% CI) P
Statins
Main analysis: user vs non-user after diagnosis 394 3058 15653 0.83 (0.64, 1.08) 0.07
Sub group analyses: user vs non-user after diagnosis, restricted to
BMI before diagnosis, p25 kgm2 68 545 2970 0.75 (0.36, 1.58) 0.46
BMI before diagnosis, 25–o30 kgm 2 97 726 3730 0.80 (0.47, 1.39) 0.43
BMI before diagnosis, 430 kgm 2 141 1144 5606 0.97 (0.63, 1.49) 0.89
Sensitivity analyses: user vs non-user after diagnosis
Stage at diagnosis available (and adjusted for)b 163 1530 7281 0.98 (0.67, 1.46) 0.96
Increasing lag to 1 yearc 394 3058 15653 0.88 (0.67, 1.16) 0.36
Excluding patients with p6 months follow-up after diagnosisd 523 3306 17249 0.88 (0.69, 1.11) 0.28
b-Blockers
Main analysis: user vs non-user after diagnosis 394 3058 15653 0.87 (0.68, 1.10) 0.24
Sub group analyses: user vs non-user after diagnosis, restricted to
BMI before diagnosis, p25 kgm2 68 545 2970 0.97 (0.48, 1.94) 0.93
BMI before diagnosis, 25–o30 kgm 2 97 726 3730 1.16 (0.72, 1.87) 0.55
BMI before diagnosis, 430 kgm 2 141 1144 5606 0.69 (0.45, 1.04) 0.07
Sensitivity analyses: user vs non-user after diagnosis
Stage at diagnosis available (and adjusted for)b 163 1530 7281 0.88 (0.60, 1.29) 0.51
Increasing lag to 1 yearc 394 3058 15653 0.91 (0.71, 1.16) 0.43
Excluding patients with p6 months follow-up after diagnosisd 523 3306 17249 0.83 (0.67, 1.03) 0.10
Low-dose aspirin
Main analysis: user vs non-user after diagnosis 394 3058 15653 0.91 (0.69, 1.20) 0.52
Sub group analyses: user vs non-user after diagnosis, restricted to
BMI before diagnosis, p25 kgm2 68 545 2970 0.95 (0.47, 1.89) 0.88
BMI before diagnosis, 25–o30 kgm 2 97 726 3730 0.62 (0.33, 1.16) 0.13
BMI before diagnosis, 430 kgm 2 141 1144 5606 0.75 (0.47, 1.21) 0.24
Sensitivity analyses: user vs non-user after diagnosis
Stage at diagnosis available (and adjusted for)b 163 1530 7281 0.93 (0.61, 1.41) 0.72
Increasing lag to 1 yearc 394 3058 15653 0.90 (0.68, 1.20) 0.47
Excluding patients with p6 months follow-up after diagnosisd 523 3306 17249 0.98 (0.77, 1.25) 0.90
Abbreviations: BMI¼body mass index; CI¼ confidence interval; HR¼ hazard ratio.
aAdjusted for year of diagnosis, age at diagnosis, surgery within 6 months, radiotherapy within 6 months, chemotherapy within 6 months, deprivation (in fifths), comorbidities (before diagnosis,
including cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, myocardial infarction, peptic ulcer disease, peripheral vascular disease and renal disease),
medication use after diagnosis (time varying, including statins, b-blockers and low-dose aspirin).
bAdjusted model contains all variables in a along with stage at diagnosis (in individuals with stage available).
cIncreasing lag to 1 year among individuals living more than 1 year after cancer diagnosis.
dExcluding patients with r6 months follow-up after diagnosis with cases followed from 6 months after diagnosis
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information on number of prescriptions was available and included
in analyses. Earlier studies have shown that tumour cells interact
with platelets and platelets including platelet activation have
been linked to key steps in cancer progression (Bambace and
Holmes, 2011, Gay and Felding-Habermann, 2011). Although post
diagnostic the use of aspirin has also been linked to a reduced risk
of cancer-specific mortality or recurrence in prostate (Choe et al,
2012), breast (Kwan et al, 2007, Holmes et al, 2010) and colorectal
cancer (Liao et al, 2012, Ng et al, 2014) patients, there was no
evidence of an association between use of low-dose aspirin and EC
survival in the current study.
This study has several strengths. It is the first study to examine the
associations between the use of b-blockers after diagnosis in relation
to EC survival. Our cohort of EC patients represents the largest to
date to assess the association between statin or low-dose aspirin use
and EC survival. Linkage of NCDR and ONS enabled robust
verification of EC cases and deaths. GP prescription records also
allowed adequate measure of drug exposure including type, dose and
timing of use. Importantly, we regarded drug use as time-dependent
covariates in order to avoid immortal time bias. The study also
benefitted from a relatively long follow-up period of up to 16 years.
There are some limitations of this study to consider. We did not
have information on low-dose aspirin sold over-the-counter
(OTC), although previous investigation within the GPRD has
found that the majority of chronic aspirin use was captured by
prescription records (Yang et al, 2008). Misclassification of statin
use is also possible due to OTC use, but only low-dose 10mg
simvastatin is available OTC in the United Kingdom and only from
2004 (Stewart et al, 2010); therefore, the risk of bias due to drug
misclassification is greatly reduced. Furthermore, missing OTC
drug exposure has previously been shown not to be a large source
of bias when estimating drug-disease association (Yood et al,
2007). A proportion of our cohort had missing data for tumour
stage (50%), which reduced the number of patients included in our
stage-adjusted model and could therefore potentially result in some
residual confounding. However, results from sensitivity analysis,
which additionally adjusted for stage, were similar to the main
analysis. A limitation of this study was our inability to perform
stratified analysis by histological type, although the majority of EC
cases are Type I and survival is generally better for this group of
patients compared with those with Type II disease (Morice et al,
2016). One previous study indicated that a beneficial effect of
statins may exist for Type II EC only (Nevadunsky et al, 2015);
however, a subsequent report saw no difference in survival for
statin users between older patients with Type I and II tumours
(Yoon et al, 2015). Recent advances have also been made in our
knowledge of molecular subtypes of EC, with the 2013 Integrated
Genomic consortium classifying tumours into four categories that
have distinct prognoses (Cancer Genome Atlas Research Network,
2013). It is therefore a limitation of this study that we are unable to
investigate our associations by molecular subtypes and future
molecular pathology epidemiology studies may be warranted.
In conclusion, the findings from this large population-based
study suggested no associations between post-diagnostic use of
statins, b-blockers or low-dose aspirins and EC-specific mortality.
Considering that this study is the first to assess the influence of
b-blockers use and EC survival, the inconsistent and very limited
findings from previous studies of statin or low-dose aspirin use and
overall survival, further high-quality studies are warranted.
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